Teva Pharmaceutical Industries (TLV: TEVA) is expected to cut 20-25% of its 6,860-strong workforce in Israel, financial news website Calcalist reported on Thursday.
At least 1,000 more in the United States are also poised to lose their jobs, according to reports. The world's largest generic drugmaker will send out termination letters to a significant proportion of its 10,000 US employees in the coming weeks.
The news comes as the embattled CEO Kare Schultz continues to sell off the company's assets to meet its debt payments. It is part of Teva's cost-cutting programme, which is expected to be rolled out imminently.
The company published its third-quarter results earlier this month. Teva expects to miss its 2017 profit forecasts because of the falling prices of generics in the US as well as the steadily declining sales of its multiple sclerosis drug Copaxone.
"It will be an absolute priority for me that we stabilise the company's operating profit and cash flow in order to improve our financial profile," Schultz said in a post-earnings call with analysts.
Meanwhile, interim chief financial officer Mike McClellan commented that the company was "working on a 2018 plan and evaluating all options".
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US